Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Page 1
Improved estimation of overall survival and progression-free survival for state transition modeling.
Wigfield PC, Heeg B, Ouwens M. Wigfield PC, et al. Among authors: ouwens m. J Comp Eff Res. 2024 Jan;13(1):e230031. doi: 10.57264/cer-2023-0031. Epub 2023 Dec 15. J Comp Eff Res. 2024. PMID: 38099516 Free PMC article.
Fitting poorly to data over the trial period can then have implications for long-term extrapolations. A novel estimation approach is defined in which the predicted overall survival (OS) and progression-free survival (PFS) extrapolations from an STM are optimized to provide …
Fitting poorly to data over the trial period can then have implications for long-term extrapolations. A novel estimation approach is …
COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
Meeraus W, Stuurman AL, Durukal I, Conde-Sousa E, Lee A, Maria AS, Furtado BE, Ouwens M, Gray CM, Valverde DA, da Silva HG, Taylor S. Meeraus W, et al. Among authors: ouwens m. Vaccine. 2023 Oct 6;41(42):6366-6378. doi: 10.1016/j.vaccine.2023.08.085. Epub 2023 Sep 12. Vaccine. 2023. PMID: 37704499 Free article.
BACKGROUND: Although COVID-19 booster vaccination is widely recommended, there is limited long-term, population-level, real-world evidence on the magnitude of improved protection against severe COVID-19 conferred by boosting with monovalent COVID-19 vaccines developed agai …
BACKGROUND: Although COVID-19 booster vaccination is widely recommended, there is limited long-term, population-level, real-world evi …
Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial.
Tank A, Johnston SC, Jain R, Amarenco P, Mellström C, Rikner K, Denison H, Ladenvall P, Knutsson M, Himmelmann A, Evans SR, James S, Molina CA, Wang Y, Ouwens M. Tank A, et al. Among authors: ouwens m. BMJ Neurol Open. 2023 Aug 24;5(2):e000478. doi: 10.1136/bmjno-2023-000478. eCollection 2023. BMJ Neurol Open. 2023. PMID: 37637218 Free PMC article.
METHODS: Cost-effectiveness was evaluated using a decision tree and Markov model with a short-term and long-term (30-year) horizon. Stroke, mortality, bleeding and EuroQol-5 Dimension (EQ-5D) data from THALES were used to estimate short-term outcomes. ...Heal …
METHODS: Cost-effectiveness was evaluated using a decision tree and Markov model with a short-term and long-term (30-year) hor …
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C, Ouwens M, Hartig-Merkel W, Drikite L, Rebry G, Carmona A, Stuurman AL, Chi Nguyen TY, Mena G, Mira-Iglesias A, Icardi G, Otero-Romero S, Baumgartner S, Martin C, Taylor S, Bollaerts K. Meeraus W, et al. Among authors: ouwens m. Lancet Reg Health Eur. 2023 Jul 1;31:100675. doi: 10.1016/j.lanepe.2023.100675. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37547274 Free PMC article.
BACKGROUND: Vaccine effectiveness (VE) studies with long-term follow-up are needed to understand durability of protection against severe COVID-19 outcomes conferred by primary-series vaccination in individuals not receiving boosters. ...
BACKGROUND: Vaccine effectiveness (VE) studies with long-term follow-up are needed to understand durability of protection against sev …
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial.
Willigers BJA, Ouwens M, Briggs A, Heerspink HJL, Pollock C, Pecoits-Filho R, Tangri N, Kovesdy CP, Wheeler DC, Garcia Sanchez JJ. Willigers BJA, et al. Among authors: ouwens m. Adv Ther. 2023 Jun;40(6):2741-2751. doi: 10.1007/s12325-023-02503-3. Epub 2023 Apr 18. Adv Ther. 2023. PMID: 37071317 Free PMC article.
INTRODUCTION: Clinical trials often have short follow-ups, and long-term outcomes such as survival must be extrapolated. Current extrapolation methods often produce a wide range of survival values. ...CONCLUSIONS: Using expert opinion in a Bayesian analysis provided a robu …
INTRODUCTION: Clinical trials often have short follow-ups, and long-term outcomes such as survival must be extrapolated. Current extr …
Activating Relatives to Get Involved in Care After Surgery: Protocol for a Prospective Cohort Study.
Musters SCW, Kreca S, van Dieren S, van der Wal-Huisman H, Romijn JA, Chaboyer W, Nieveen van Dijkum EJM, Eskes AM; ARTIS Consortium. Musters SCW, et al. JMIR Res Protoc. 2023 Jan 6;12:e38028. doi: 10.2196/38028. JMIR Res Protoc. 2023. PMID: 36440980 Free PMC article.
BACKGROUND: Postoperative complications and readmissions to hospital are factors known to negatively influence the short- and long-term quality of life of patients with gastrointestinal cancer. Active family involvement in activities, such as fundamental care activities, h …
BACKGROUND: Postoperative complications and readmissions to hospital are factors known to negatively influence the short- and long-term …
Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.
Rhodes K, Jenkins M, de Nigris E, Aurivillius M, Ouwens M. Rhodes K, et al. Among authors: ouwens m. BMC Med Res Methodol. 2022 May 25;22(1):150. doi: 10.1186/s12874-022-01616-7. BMC Med Res Methodol. 2022. PMID: 35614467 Free PMC article.
BACKGROUND: The major drivers of cost-effectiveness for chronic obstructive pulmonary disease (COPD) therapies are the occurrence of exacerbations and deaths. Exacerbations, including acute and long-term events, can cause worsening of COPD and lead to an increased risk of …
BACKGROUND: The major drivers of cost-effectiveness for chronic obstructive pulmonary disease (COPD) therapies are the occurrence of exacerb …
Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease.
Cabrera C, Quélen C, Ouwens M, Hedman K, Rigney U, Quint JK. Cabrera C, et al. Among authors: ouwens m. Ann Epidemiol. 2022 Mar;67:19-28. doi: 10.1016/j.annepidem.2021.11.004. Epub 2021 Nov 16. Ann Epidemiol. 2022. PMID: 34798296 Free article.
Future studies should continue to investigate causal inference methods and their capability to estimate the long-term outcomes of treatment in COPD....
Future studies should continue to investigate causal inference methods and their capability to estimate the long-term outcomes of tre …
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W, van Keep M, Elroy P, Perez ID, Ouwens MJNM, Sarbajna T, Zhang Y, Greystoke A. Dunlop W, et al. Among authors: ouwens mjnm. Pharmacoecon Open. 2022 Mar;6(2):241-252. doi: 10.1007/s41669-021-00301-7. Epub 2021 Sep 16. Pharmacoecon Open. 2022. PMID: 34532842 Free PMC article.
As patients in the study at the time of the initial submission to NICE were only followed for approximately 2 years, the long-term survival benefit that could be achieved with durvalumab was uncertain. ...Here, we demonstrate that the original cost-effectiveness model accu …
As patients in the study at the time of the initial submission to NICE were only followed for approximately 2 years, the long-term su …
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Ouwens MJNM, et al. Pharmacoeconomics. 2019 Sep;37(9):1129-1138. doi: 10.1007/s40273-019-00806-4. Pharmacoeconomics. 2019. PMID: 31102143 Free PMC article.
BACKGROUND: Standard parametric survival models are commonly used to estimate long-term survival in oncology health technology assessments; however, they can inadequately represent the complex pattern of hazard functions or underlying mechanism of action (MoA) of immuno-on …
BACKGROUND: Standard parametric survival models are commonly used to estimate long-term survival in oncology health technology assess …
17 results